Loading...
Pak Fah Yeow International Limited, an investment holding company, manufactures, markets, and distributes healthcare products under the Hoe Hin brand name in the People’s Republic of China, Southeast Asia, North America, the United Kingdom, and internationally. The last earnings update was 149 days ago. More info.
7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
---|---|---|---|---|---|---|
Pak Fah Yeow International (239) | 2.3% | 5.9% | 2.3% | -8.1% | -21.1% | 14.8% |
HK Pharmaceuticals | 4.3% | 15% | -4.9% | -11% | 55.6% | 28.9% |
HK Market | 1.6% | 6.7% | 6.9% | -11% | 34.7% | 15.6% |
Below are the data sources, inputs and calculation used to determine the intrinsic value for Pak Fah Yeow International.
Data Point | Source | Value |
---|---|---|
Valuation Model | 2 Stage Free Cash Flow to Equity | |
Levered Free Cash Flow | Extrapolated from most recent financials. | See below |
Discount Rate (Cost of Equity) | See below | 8.4% |
Perpetual Growth Rate | 10-Year HK Government Bond Rate | 2% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
Data Point | Calculation/ Source | Result |
---|---|---|
Risk-Free Rate | 10-Year HK Govt Bond Rate | 2% |
Equity Risk Premium | S&P Global | 8% |
Pharmaceuticals Unlevered Beta | Simply Wall St/ S&P Global | 0.78 |
Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.776 (1 + (1- 25%) (2.61%)) |
0.791 |
Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.8 |
Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2% + (0.8 * 8%) |
8.4% |
Discounted Cash Flow Calculation for SEHK:239 using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Pak Fah Yeow International is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.
2019 | 2020 | 2021 | 2022 | 2023 | |
Levered FCF (HKD, Millions) | 63.65 | 64.74 | 65.85 | 66.97 | 68.12 |
Source | Est @ 1.71% | Est @ 1.71% | Est @ 1.71% | Est @ 1.71% | Est @ 1.71% |
Present Value Discounted (@ 8.4%) |
58.72 | 55.10 | 51.70 | 48.50 | 45.51 |
Present value of next 5 years cash flows | HK$259.53 |
Calculation | Result | |
---|---|---|
Terminal Value |
= FCF2023
× (1 + g) ÷ (Discount Rate – g)
= HK$68.12 × (1 + 2%) ÷ (8.4% – 2%) |
HK$1,086.10 |
Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)5
= HK$1,086.10 ÷ (1 + 8.4%)5 |
HK$725.62 |
Calculation | Result | |
---|---|---|
Total Equity Value |
= Present value of next 5 years cash flows +
Terminal Value
= HK$259.53 + HK$725.62 |
HK$985.15 |
Equity Value per Share (HKD) |
= Total value / Shares Outstanding
= HK$985.15 / 311.64 |
HK$3.16 |
Calculation | Result | |
---|---|---|
Value per share (HKD) | From above. | HK$3.16 |
Current discount | Discount to share price of
HK$3.07
= -1 x (HK$3.07 - HK$3.16) / HK$3.16 |
2.9% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Data Point | Source | Value |
---|---|---|
Earnings Per Share * | Company Filings (2018-06-30) in HKD | HK$0.21 |
SEHK:239 Share Price ** | SEHK (2019-02-15) in HKD | HK$3.07 |
Hong Kong Pharmaceuticals Industry PE Ratio | Median Figure of 30 Publicly-Listed Pharmaceuticals Companies | 14.33x |
Hong Kong Market PE Ratio | Median Figure of 1,482 Publicly-Listed Companies | 10.71x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Pak Fah Yeow International.
Calculation | Outcome | |
---|---|---|
PE Ratio | = SEHK:239 Share Price ÷ EPS (both in HKD) = 3.07 ÷ 0.21 |
14.42x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
Data Point | Source | Value |
---|---|---|
PE Ratio | See PE Ratio Section | 14.42x |
Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts |
10.1%per year |
Hong Kong Pharmaceuticals Industry PEG Ratio | Median Figure of 16 Publicly-Listed Pharmaceuticals Companies | 1.12x |
Hong Kong Market PEG Ratio | Median Figure of 465 Publicly-Listed Companies | 0.76x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
Data Point | Source | Value |
---|---|---|
Book Value per Share | Company Filings (2018-06-30) in HKD | HK$2.39 |
SEHK:239 Share Price * | SEHK (2019-02-15) in HKD | HK$3.07 |
Hong Kong Pharmaceuticals Industry PB Ratio | Median Figure of 34 Publicly-Listed Pharmaceuticals Companies | 1.44x |
Hong Kong Market PB Ratio | Median Figure of 2,117 Publicly-Listed Companies | 0.97x |
Calculation | Outcome | |
---|---|---|
PB Ratio | = SEHK:239 Share Price ÷ Book Value per Share (both in HKD) = 3.07 ÷ 2.39 |
1.28x |
* Primary Listing of Pak Fah Yeow International.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
Data Point | Source | Value (per year) |
---|---|---|
SEHK:239 Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts | 10.1% |
Hong Kong Pharmaceuticals Industry Earnings Growth Rate | Market Cap Weighted Average | 14.1% |
Hong Kong Pharmaceuticals Industry Revenue Growth Rate | Market Cap Weighted Average | 15.1% |
Hong Kong Market Earnings Growth Rate | Market Cap Weighted Average | 11.7% |
Hong Kong Market Revenue Growth Rate | Market Cap Weighted Average | 10% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Data Point | Source | Value |
---|---|---|
Past Financials | Company Filings (7 months ago) | See Below |
Future Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
Date (Data in HKD Millions) | Revenue | Cash Flow | Net Income * |
---|---|---|---|
2018-06-30 | 146 | 63 | 66 |
2018-03-31 | 163 | 81 | 84 |
2017-12-31 | 180 | 99 | 103 |
2017-09-30 | 183 | 85 | 104 |
2017-06-30 | 186 | 72 | 106 |
2017-03-31 | 185 | 69 | 84 |
2016-12-31 | 183 | 65 | 61 |
2016-09-30 | 176 | 67 | 48 |
2016-06-30 | 170 | 69 | 34 |
2016-03-31 | 176 | 71 | 48 |
2015-12-31 | 183 | 72 | 61 |
2015-09-30 | 189 | 72 | 91 |
*GAAP earnings excluding extraordinary items.
Data Point | Source | Value |
---|---|---|
Past Financials | Company Filings (7 months ago) | See Below |
Future Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
All data from Pak Fah Yeow International Company Filings, last reported 7 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
Date (Data in HKD Millions) | EPS * |
---|---|
2018-06-30 | 0.21 |
2018-03-31 | 0.27 |
2017-12-31 | 0.33 |
2017-09-30 | 0.33 |
2017-06-30 | 0.34 |
2017-03-31 | 0.27 |
2016-12-31 | 0.20 |
2016-09-30 | 0.15 |
2016-06-30 | 0.11 |
2016-03-31 | 0.15 |
2015-12-31 | 0.20 |
2015-09-30 | 0.29 |
*GAAP earnings excluding extraordinary items.
How has Pak Fah Yeow International performed over the past 5 years?
All data from Pak Fah Yeow International Company Filings, last reported 7 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
Date (Data in HKD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
---|---|---|---|---|
2018-06-30 | 146.43 | 66.34 | 32.05 | |
2018-03-31 | 163.09 | 84.46 | 32.94 | |
2017-12-31 | 179.74 | 102.59 | 33.84 | |
2017-09-30 | 183.04 | 104.38 | 32.96 | |
2017-06-30 | 186.34 | 106.18 | 32.09 | |
2017-03-31 | 184.75 | 83.69 | 31.37 | |
2016-12-31 | 183.16 | 61.20 | 30.65 | |
2016-09-30 | 176.47 | 47.70 | 31.20 | |
2016-06-30 | 169.78 | 34.20 | 31.75 | |
2016-03-31 | 176.18 | 47.61 | 32.12 | |
2015-12-31 | 182.57 | 61.01 | 32.48 | |
2015-09-30 | 188.88 | 91.50 | 33.86 | |
2015-06-30 | 195.20 | 121.98 | 35.23 | |
2015-03-31 | 191.33 | 134.22 | 34.08 | |
2014-12-31 | 187.45 | 146.47 | 32.93 | |
2014-09-30 | 175.76 | 121.12 | 31.37 | |
2014-06-30 | 164.07 | 95.78 | 29.80 | |
2014-03-31 | 163.04 | 83.33 | 29.01 | |
2013-12-31 | 162.02 | 70.88 | 28.22 | |
2013-09-30 | 148.83 | 68.31 | 26.69 | |
2013-06-30 | 135.65 | 65.74 | 25.16 | |
2013-03-31 | 132.56 | 65.04 | 24.89 | |
2012-12-31 | 129.46 | 64.34 | 24.61 | |
2012-09-30 | 129.87 | 55.97 | 24.67 | |
2012-06-30 | 130.28 | 47.59 | 24.73 | |
2012-03-31 | 123.51 | 46.91 | 24.23 |
*GAAP earnings excluding extraordinary items.
How is Pak Fah Yeow International's financial health and their level of debt?
All data from Pak Fah Yeow International Company Filings, last reported 7 months ago.
Date (Data in HKD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
---|---|---|---|
2018-06-30 | 745.66 | 24.94 | 148.24 |
2018-03-31 | 745.66 | 24.94 | 148.24 |
2017-12-31 | 748.51 | 26.66 | 141.83 |
2017-09-30 | 748.51 | 26.66 | 141.83 |
2017-06-30 | 694.11 | 27.73 | 120.55 |
2017-03-31 | 694.11 | 27.73 | 120.55 |
2016-12-31 | 633.51 | 27.46 | 89.34 |
2016-09-30 | 633.51 | 27.46 | 89.34 |
2016-06-30 | 589.43 | 30.36 | 51.67 |
2016-03-31 | 589.43 | 30.36 | 51.67 |
2015-12-31 | 624.39 | 35.14 | 19.86 |
2015-09-30 | 624.39 | 35.14 | 19.86 |
2015-06-30 | 615.72 | 37.82 | 47.86 |
2015-03-31 | 615.72 | 37.82 | 47.86 |
2014-12-31 | 622.63 | 43.76 | 14.96 |
2014-09-30 | 622.63 | 43.76 | 14.96 |
2014-06-30 | 548.21 | 53.42 | 39.66 |
2014-03-31 | 548.21 | 53.42 | 39.66 |
2013-12-31 | 516.86 | 49.95 | 16.17 |
2013-09-30 | 516.86 | 49.95 | 16.17 |
2013-06-30 | 486.05 | 49.47 | 23.70 |
2013-03-31 | 486.05 | 49.47 | 23.70 |
2012-12-31 | 477.44 | 56.00 | 25.41 |
2012-09-30 | 477.44 | 56.00 | 25.41 |
2012-06-30 | 414.80 | 56.90 | 28.69 |
2012-03-31 | 414.80 | 56.90 | 28.69 |
What is Pak Fah Yeow International's current dividend yield, its reliability and sustainability?
Data Point | Source | Value |
---|---|---|
Past Annualized Dividend Yield | S&P Global Market Data | See Below |
Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
Future Dividends per Share Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
Hong Kong Pharmaceuticals Industry Average Dividend Yield | Market Cap Weighted Average of 24 Stocks | 1.5% |
Hong Kong Market Average Dividend Yield | Market Cap Weighted Average of 916 Stocks | 3.5% |
Hong Kong Minimum Threshold Dividend Yield | 10th Percentile | 1.1% |
Hong Kong Bottom 25% Dividend Yield | 25th Percentile | 2% |
Hong Kong Top 25% Dividend Yield | 75th Percentile | 5.5% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
Date (Data in HK$) | Dividend per share (annual) | Avg. Yield (%) |
---|---|---|
2018-04-19 | 0.127 | 3.965 |
2017-04-18 | 0.125 | 3.645 |
2017-03-27 | 0.125 | 3.534 |
2016-04-15 | 0.125 | 3.370 |
2016-03-30 | 0.125 | 3.237 |
2015-12-15 | 0.202 | 4.976 |
2015-09-11 | 0.206 | 5.181 |
2015-08-26 | 0.206 | 5.556 |
2015-04-16 | 0.179 | 4.355 |
2015-03-26 | 0.179 | 4.875 |
2014-08-25 | 0.158 | 4.855 |
2014-06-25 | 0.155 | 4.728 |
2014-04-16 | 0.154 | 5.247 |
2014-03-27 | 0.154 | 5.563 |
2013-04-17 | 0.109 | 4.252 |
2013-03-27 | 0.109 | 4.801 |
2012-08-31 | 0.108 | 5.085 |
2012-06-28 | 0.103 | 5.137 |
2012-03-27 | 0.108 | 5.401 |
2011-12-22 | 0.063 | 3.025 |
2011-06-28 | 0.077 | 3.624 |
2011-03-23 | 0.128 | 5.287 |
2010-04-29 | 0.107 | 5.023 |
2010-04-22 | 0.107 | 5.841 |
2009-09-21 | 0.060 | 4.498 |
2009-04-22 | 0.100 | 9.606 |
2009-02-16 | 0.043 | 6.299 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
Mr. Wee Sean Gan has been the Chief Executive Officer of Pak Fah Yeow International Ltd. since September 1, 2011 and serves as its Executive Chairman. Mr. Gan also serves as an Island Command Vice President of the St. John's Ambulance Brigade in Hong Kong. He has been actively involved in the management of Pak Fah Yeow since 1971. He served as Acting Chief Executive Officer of Pak Fah Yeow International Ltd., from April 21, 2008 to September 1, 2011. Mr. Gan has been an Executive Director of Pak Fah Yeow International Ltd. since October 8, 1991. He was the Chairman and Vice Chairman of Chung Sing Benevolent Society from 1987 to 1990 and from 1981 to 1986, respectively. He was the Chairman of the Malaysian Association in Hong Kong from 1987 to 1989 and was a Founder Member of the Institute of Marketing in Hong Kong. Mr. Gan is a Fellow of the Institute of Chartered Secretaries and Administrators and the Chartered Institute of Marketing.
Average tenure and age of the Pak Fah Yeow International board of directors in years:
Wee Gan became the CEO of Pak Fah Yeow International Limited (HKG:239) in 2011. … This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Wee Gan's Compensation Compare With Similar Sized Companies?
Simply Wall St - – Full articleEvery investor in Pak Fah Yeow International Limited (HKG:239) should be aware of the most powerful shareholder groups. … Pak Fah Yeow International is not a large company by global standards. … See our latest analysis for Pak Fah Yeow International
Simply Wall St - – Full articleHistorically, Pak Fah Yeow International Limited (HKG:239) has paid dividends to shareholders, and these days it yields 4.3%. … Does Pak Fah Yeow International tick all the boxes of a great dividend stock? … Check out our latest analysis for Pak Fah Yeow International
Simply Wall St - – Full articleWhile some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. … Our data shows Pak Fah Yeow International has a return on equity of 8.9% for the last year. … Return on Equity = Net Profit ÷ Shareholders' Equity
Simply Wall St - – Full articleThis article is written for those who want to get better at using price to earnings ratios (P/E ratios). … We'll look at Pak Fah Yeow International Limited's (HKG:239) P/E ratio and reflect on what it tells us about the company's share price. … Pak Fah Yeow International has a price to earnings ratio of 14.52, based on the last twelve months.
Simply Wall St - – Full articleFirst, this article will compare CEO compensation with compensation at similar sized companies. … How Does Wee Gan's Compensation Compare With Similar Sized Companies. … According to our data, Pak Fah Yeow International Limited has a market capitalization of HK$938m, and pays its CEO total annual compensation worth HK$7m.
Simply Wall St - – Full articleA large part of investment returns can be generated by dividend-paying stock given their role in compounding returns over time. … Historically, Pak Fah Yeow International Limited (HKG:239) has paid dividends to shareholders, and these days it yields 4.0%. … Let's dig deeper into whether Pak Fah Yeow International should have a place in your portfolio.
Simply Wall St - – Full articleImportant news for shareholders and potential investors in Pak Fah Yeow International Limited (HKG:239): The dividend payment of HK$0.078 per share will be distributed into shareholder on 17 August 2018, and the stock will begin trading ex-dividend at an earlier date, 09 July 2018. … Investors looking for higher income-generating stocks to add to their portfolio should keep reading, as I take a deeper dive into Pak Fah Yeow International's latest financial data to analyse its dividend attributes. … When assessing a stock as a potential addition to my dividend Portfolio, I look at these five areas:
Simply Wall St - – Full articleAs an investor, I look for investments which does not compromise one fundamental factor for another. … By this I mean, I look at stocks holistically, from their financial health to their future outlook. … is a company with great financial health as well as a.
Simply Wall St - – Full articleHow does 239’s operating cash flow stack up against its debt? … Moreover, 239 has produced cash from operations of HK$65.42M over the same time period, resulting in an operating cash to total debt ratio of 238.22%, meaning that 239’s debt is appropriately covered by operating cash. … In 239's, case, the ratio of 100x suggests that interest is comfortably covered, which means that lenders may be inclined to lend more money to the company, as it is seen as safe in terms of payback.Next Steps: 239’s high cash coverage and low debt levels indicate its ability to utilise its borrowings efficiently in order to generate ample cash flow.
Simply Wall St - – Full article
Pak Fah Yeow International Limited, an investment holding company, manufactures, markets, and distributes healthcare products under the Hoe Hin brand name in the People’s Republic of China, Southeast Asia, North America, the United Kingdom, and internationally. It operates through three segments: Healthcare, Property Investments, and Treasury Investments. The company offers Hoe Hin White Flower Embrocation or Hoe Hin Pak Fah Yeow, a medicated oil; Hoe Hin Strain Relief; and Hoe Hin White Flower ointment products, as well as Fúzai 239, a floral-scented White Flower Embrocation. It also provides advertising agency services. Pak Fah Yeow International Limited is headquartered in Wan Chai, Hong Kong.
Name: | Pak Fah Yeow International Limited |
239 | |
Exchange: | SEHK |
Founded: | |
HK$956,734,800 | |
311,640,000 | |
Website: | http://www.whiteflower.com |
Address: |
Pak Fah Yeow International Limited 200 Gloucester Road, 11th Floor, Wan Chai, Hong Kong |
Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
---|---|---|---|---|---|---|---|
SEHK | 239 | Ordinary Shares | The Stock Exchange of Hong Kong Ltd. | HK | HKD | 15. Sep 1992 |
Pharmaceuticals | |
Pharmaceuticals & Biotech |
Area | Date (UTC time) |
---|---|
Company Analysis updated: | 2019/02/15 12:46 |
End of day share price update: | 2019/02/15 00:00 |
Last earnings filing: | 2018/09/19 |
Last earnings reported: | 2018/06/30 |
Last annual earnings reported: | 2017/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.